Eligibility of rheumatoid arthritis patients seen in clinical practice for rheumatoid arthritis clinical trials: Comment on the article by Sokka and Pincus (multiple letters) [2]

Arthritis and Rheumatism

Volumn 48, Issue 12, 2003, Pages 3611-

  Yazici, Yusuf ^a,b   Erkan, Doruk ^b  

^a LONG ISLAND COLLEGE HOSPITAL   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTHRALGIA; CLINICAL FEATURE; DISEASE SEVERITY; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0348111226     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11336     Document Type: Letter

References (6)

1. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor a agents in rheumatoid arthritis. Arthritis Rheum 2003;48:313-8.
2. Yazici Y, Erkan D, Paget SA. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum 2003;48:2769-72.
3. Erkan D, Yazici Y, Harrison MJ, Paget SA. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Rheum 2002;47:285-90.
4. Erkan D, Yazici Y, Harrison MJ, Paget SA. The impact of pharmocoeconomics on the treatment of rheumatoid arthritis. Drug Benefit Trends 2002;14 Suppl B:32-8.
5. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41:1037-41.
6. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002;41:793-800.